Affibody and Agilent Technologies to Develop Robust Protein Sample
Under the agreement, Affibody will deliver highly specific and robust affinity capture ligands that will enable Agilent to expand its market-leading Multiple Affinity Removal System technology with new product configurations. These products will enable scientists involved in biomarker discovery from human serum/plasma to continue to dig deeper into the serum proteome, in order to discover and identify potential biomarkers that can be used for human disease diagnosis, monitoring of therapeutic intervention, and prognosis. The robustness of the Affibody® ligand permits unsurpassed reproducibility for sample-to-sample comparison, resulting in greater certainty and clarity of scientific data.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.